Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
W
Wafa, Hazem
UZ Leuven
(
P 198
)
XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Hazem Wafa
Favorite
Wagner, Andrew
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
(
P 102
)
EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Andrew Wagner
Favorite
(
P 143
)
A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Andrew Wagner
Favorite
(
P 156
)
MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Andrew Wagner
Favorite
(
P 167
)
STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Andrew Wagner
Favorite
(
P 320
)
PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Andrew Wagner
Favorite
Wagner, Andrew J.
Department of Oncology, Dana-Farber Cancer Institute
(
P 314
)
A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Andrew J. Wagner
Favorite
Wagner, Lars
Department of Pediatrics, Division of Hematology/Oncology, Duke University
(
P 171
)
CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Lars Wagner
Favorite
(
P 237
)
EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
Wagner, Michael
University of Washington/Fred Hutch Cancer Center
(
P 063
)
A RETROSPECTIVE COHORT ANALYSIS EVALUATING THE NATURAL HISTORY AND CHARACTERISTICS OF ANGIOSARCOMAS OF THE BREAST
Michael Wagner
Favorite
Wahlig, Brian
Mayo Clinic
(
P 278
)
ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Brian Wahlig
Favorite
(
P 293
)
OUTCOMES OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE LOWER EXTREMITY
Brian Wahlig
Favorite
(
P 296
)
PET IMAGING VERSUS CLINICAL EXAMINATION IN DETERMINING LYMPH NODE INVOLVEMENT IN MERKEL CELL CARCINOMA OF THE EXTREMITY
Brian Wahlig
Favorite
Waise, Sara
Francis Crick Institute
(
P 252
)
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Sara Waise
Favorite
Walker, Phillip
Caris Life Science
(
P 234
)
DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Phillip Walker
Favorite
Walker, Victoria
University of Florida
(
P 177
)
GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
Victoria Walker
Favorite
Wang, Chao-Chi
Laboratory of Experimental Oncology, KU Leuven
(
P 198
)
XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Chao-Chi Wang
Favorite
Wang, Chen
Abbisko Therapeutics
(
P 164
)
PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Chen Wang
Favorite
Wang, David
Stanford University School of Medicine
(
P 130
)
MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
David Wang
Favorite
Wang, Dian
Rush University Medical Center
(
P 086
)
RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Dian Wang
Favorite
(
P 206
)
RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Dian Wang
Favorite
Wang, Fang
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(
P 216
)
LONG TERM SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH PRIMARY RETROPERITONEAL LEIOMYOSARCOMA UNDERGOING SURGERIES: REAL WORLD DATA FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Fang Wang
Favorite
(
P 223
)
SURGICAL RESECTION OF RETROPERITONEAL LEIOMYOSARCOMA IN 97 CONSECUTIVE PATIENTS - EXPERIENCES FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Fang Wang
Favorite
Wang, Jiping
TARPSWG
(
P 214
)
EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Jiping Wang
Favorite
Wang, Jun
Department of Anesthesiology, Peking University International Hospital
(
P 211
)
ANESTHESIA MANAGEMENTS AND POSTOPERATIVE MORTALITIES IN RETROPERITONEAL SARCOMA PATIENTS EXPERIENCING MASSIVE BLOOD TRANSFUSION DURING SURGERIES
Jun Wang
Favorite
(
P 223
)
SURGICAL RESECTION OF RETROPERITONEAL LEIOMYOSARCOMA IN 97 CONSECUTIVE PATIENTS - EXPERIENCES FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Jun Wang
Favorite
Wang, Pin-Yi
Center for Childhood Cancer, Nationwide Children's Hospital
(
P 140
)
TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Pin-Yi Wang
Favorite
Wang, Ruoxi
Adaptimmune
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Ruoxi Wang
Favorite
Wang, Tianjiao
Adaptimmune
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Tianjiao Wang
Favorite
Wang, Victoria
University of California San Francisco
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Victoria Wang
Favorite
Wang, Wei-Lien
The University of Texas MD Anderson Cancer Center
(
P 013
)
A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Wei-Lien Wang
Favorite
Wang, Xue
UBC
(
P 306
)
THERMAL NECROSIS IN ORTHOPAEDIC BONE TUMORS
Xue Wang
Favorite
Wang, Ying
BC Cancer
(
P 074
)
EWING SARCOMA AND RHABDOMYOSARCOMA PATIENT OUTCOME VARIATIONS BASED ON TREATMENT CENTRE VOLUME
Ying Wang
Favorite
Wang, Yong
University of Copenhagen
(
P 235
)
ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Yong Wang
Favorite
Wan, Jessica
Foghorn Therapeutics
(
P 187
)
PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Jessica Wan
Favorite
WAN, YUANYUAN
Peking University International Hospital
(
P 213
)
EPITHELIOID INFLAMMATORY MYOFIBROBLASTIC SARCOMA WITH LEUKEMOID REACTION
YUANYUAN WAN
Favorite
Ward, Abigail
Dana-Farber Cancer Institute
(
P 239
)
FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Abigail Ward
Favorite
Wardelmann, Eva
Universitätsklinikum Münster
(
P 231
)
COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Eva Wardelmann
Favorite
Waspe, Adam
Hospital for Sick Children
(
P 124
)
EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Adam Waspe
Favorite
Wasp, Garrett Thomas
Dartmouth Cancer Center at Dartmouth-Hitchcock
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Garrett Thomas Wasp
Favorite
Watanabe, Mika
Tohoku Kosai Hospital
(
P 091
)
THE PROGNOSIS OF PULMONARY METASTASIS AFTER THE SURGERY FOR PRIMARY LESION IN ELDERLY HIGH-GRADE SARCOMA PATIENTS
Mika Watanabe
Favorite
(
P 209
)
THE OUTCOME OF R1 EXCISION COMBINED WITH ADJUVANT RADIOTHERAPY FOR SOFT TISSUE SARCOMA IN ELDERLY PATIENTS
Mika Watanabe
Favorite
Watanuki, Mnenori
Department of Orthopaedic Surgery Tohoku University Graduate School of Medicine
(
P 209
)
THE OUTCOME OF R1 EXCISION COMBINED WITH ADJUVANT RADIOTHERAPY FOR SOFT TISSUE SARCOMA IN ELDERLY PATIENTS
Mnenori Watanuki
Favorite
Watanuki, Munenori
Tohoku University School of Medicine
(
P 091
)
THE PROGNOSIS OF PULMONARY METASTASIS AFTER THE SURGERY FOR PRIMARY LESION IN ELDERLY HIGH-GRADE SARCOMA PATIENTS
Munenori Watanuki
Favorite
Watson, Geoffrey
Department of Medical Oncology - Mount Sinai Hospital; University of Toronto
(
P 068
)
CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Geoffrey Watson
Favorite
Watters, Rebecca
University of Pittsburgh Medical Center
(
P 025
)
INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Rebecca Watters
Favorite
(
P 087
)
RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Rebecca Watters
Favorite
(
P 244
)
MUTATIONAL BURDEN OF COPY NUMBER VARIANTS VS STRUCTURAL VARIANTS IN EXTRASKELETAL MYXOID CHONDROSARCOMA: A CASE STUDY
Rebecca Watters
Favorite
Watt, Tanya
University of Texas Southwestern Medical Center
(
P 104
)
INFANTILE EXTRARENAL SPINDLE CELL MESENCHYMAL NEOPLASMS WITH TARGETABLE EGFR KINASE DOMAIN DUPLICATIONS
Tanya Watt
Favorite
Wayne, Matt
Medical Impact Ventures
(
P 095
)
A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
Matt Wayne
Favorite
Webster, Luke
The Royal Marsden NHS Foundation Trust
(
P 152
)
FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Luke Webster
Favorite
Weinreb, Ilan
University Health Network
(
P 05
)
GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Ilan Weinreb
Favorite
Weiskittlel, Taylor
Mayo Clinic
(
P 020
)
DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Taylor Weiskittlel
Favorite
Weiss, Kurt
University of Pittsburgh Medical Center
(
P 025
)
INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Kurt Weiss
Favorite
(
P 046
)
EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Kurt Weiss
Favorite
(
P 087
)
RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Kurt Weiss
Favorite
(
P 244
)
MUTATIONAL BURDEN OF COPY NUMBER VARIANTS VS STRUCTURAL VARIANTS IN EXTRASKELETAL MYXOID CHONDROSARCOMA: A CASE STUDY
Kurt Weiss
Favorite
(
P 310
)
TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Kurt Weiss
Favorite
Weitzel, Samantha
Duke University School of Medicine
(
P 254
)
THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA
Samantha Weitzel
Favorite
Wei, Yue
Department of Anesthesiology, Peking University International Hospital
(
P 211
)
ANESTHESIA MANAGEMENTS AND POSTOPERATIVE MORTALITIES IN RETROPERITONEAL SARCOMA PATIENTS EXPERIENCING MASSIVE BLOOD TRANSFUSION DURING SURGERIES
Yue Wei
Favorite
Welch, Darcy
Moffitt Cancer Center
(
P 019
)
COUMERMYCIN-A1 (CA1) IDENTIFIED AS A FIRST-IN-CLASS CDC45-MCM-GINS HELICASE INHIBITOR OFFERING THERAPEUTIC POTENTIAL FOR OSTEOSARCOMA TREATMENT
Darcy Welch
Favorite
Werier, Joel
The Ottawa Hospital
(
P 197
)
TUMOR IMMNUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Joel Werier
Favorite
Wessel, Lauren
University of California, Los Angeles
(
P 015
)
A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Lauren Wessel
Favorite
(
P 286
)
INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Lauren Wessel
Favorite
Westwood, Andrew
Euro Ewing Consortium
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Andrew Westwood
Favorite
Wheatley, Keith
University of Birmingham
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Keith Wheatley
Favorite
Whelan, Jeremy
University College London Hospitals
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Jeremy Whelan
Favorite
White, Jeff
Beatson West of Scotland Cancer Centre
(
P 073
)
EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Jeff White
Favorite
White, Jonathan
Daiichi Sankyo, Inc., Basking Ridge, NJ, USA
(
P 038
)
TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Jonathan White
Favorite
Whittle, Sarah
Texas Children's Cancer Center, Baylor College of Medicine
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Sarah Whittle
Favorite
Wildgruber, Mortiz
(
P 257
)
SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Mortiz Wildgruber
Favorite
Wilkowski, Jodi
University of Michigan
(
P 139
)
T-CELL PROFILING IN HIGH GRADE SARCOMAS
Jodi Wilkowski
Favorite
Wilky, Breelyn
University of Colorado
(
P 041
)
UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Breelyn Wilky
Favorite
(
P 116
)
SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Breelyn Wilky
Favorite
(
P 317
)
INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Breelyn Wilky
Favorite
Williams, Dennis
Adaptimmune
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Dennis Williams
Favorite
Willingham, Stephen
Natera, Inc
(
P 047
)
FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Stephen Willingham
Favorite
Willis, Katelyn
Inhibrx, Inc
(
P 317
)
INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Katelyn Willis
Favorite
Wilps, Tyler
UC San Diego
(
P 279
)
CEMENT AUGMENTATION WITH CEPHALLOMEDUALLARY FIXATION OF PRIMARY AND METASTATIC LESIONS OF THE PROXIMAL FEMUR.
Tyler Wilps
Favorite
Wilson, David
Dalhousie University
(
P 284
)
HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
David Wilson
Favorite
Wilson, Roger
Sarcoma UK, Sarcoma Patients Euronet
(
P 115
)
PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Roger Wilson
Favorite
(
P 319
)
PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS; PROTOCOL FOR A SYSTEMATIC REVIEW
Roger Wilson
Favorite
Windle, Henry
Trinity College Dublin
(
P 235
)
ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Henry Windle
Favorite
Windsor, Rachael
Sarcoma Department, University College Hospital, London
(
P 271
)
ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Rachael Windsor
Favorite
Winfield, Jessica
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
(
P 061
)
UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Jessica Winfield
Favorite
Winstanley, Mark
Starship Children's Hospital
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Mark Winstanley
Favorite
Woessner, Mary
Research, GSK
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Mary Woessner
Favorite
Wohlford, Reagan
Indiana University
(
P 192
)
TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Reagan Wohlford
Favorite
Wojcik, Paulina
Medical University of Warsaw
(
P 169
)
WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS
Paulina Wojcik
Favorite
Wong, Andrew
Duke
(
P 034
)
REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Andrew Wong
Favorite
Wong, Boaz
The University of Ottawa
(
P 112
)
PREVALENCE AND PROGNOSTIC VALUE OF TARGETABLE RECEPTORS IN EXTRA-UTERINE LEIOMYOSARCOMA
Boaz Wong
Favorite
Wong, C.H.
The Chinese of University of Hong Kong
(
P 186
)
PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS
C.H. Wong
Favorite
Wong, Philip
Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto
(
P 068
)
CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Philip Wong
Favorite
(
P 284
)
HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Philip Wong
Favorite
Wong, Steven
Sarcoma Oncology Center
(
P 126
)
GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Steven Wong
Favorite
Wong, Suzanne
Hospital for Sick Children
(
P 124
)
EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Suzanne Wong
Favorite
Wood, Georgina
University College London Hospital
(
P 271
)
ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Georgina Wood
Favorite
Woo, Xing Yi
Bioinformatics Institute, A*STAR, Singapore
(
P 196
)
THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Xing Yi Woo
Favorite
Wozniak, Agnieszka
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute
(
P 182
)
NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Agnieszka Wozniak
Favorite
(
P 198
)
XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Agnieszka Wozniak
Favorite
Wright, Joshua
Johns Hopkins All Children's Hospital
(
P 305
)
THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Joshua Wright
Favorite
Wu, Hsin-Jung
Blueprint Medicines
(
P 187
)
PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Hsin-Jung Wu
Favorite
Wunder, Jay
Mount Sinai Hospital; University of Toronto
(
P 059
)
SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Jay Wunder
Favorite
(
P 068
)
CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Jay Wunder
Favorite
(
P 180
)
INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jay Wunder
Favorite
(
P 233
)
DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Jay Wunder
Favorite
(
P 284
)
HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Jay Wunder
Favorite
(
P 304
)
SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Jay Wunder
Favorite
Wunker, Claire
Saint Louis University
(
P 05
)
GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Claire Wunker
Favorite
(
P 124
)
EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wunker, Claire
University of Toronto
(
P 190
)
SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wu, Qing
Research Institute of the McGill University Health Centre
(
P 030
)
OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Qing Wu
Favorite
Wyles, Cody
Mayo Clinic
(
P 302
)
SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Cody Wyles
Favorite
Back to Top
